Response to DDAVP In mild Hemophilia A patients, in Search for dEterminants

Response to DDAVP In mild Hemophilia A patients, in Search for dEterminants - RISE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43824

Enrollment

281

Registered

2013-02-20

Start date

2013-02-20

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bleeding disorder hemophilia A

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Moderate/mild hemophilia: defined as a FVIII deficiency with a FVIII:C plasma concentration of 2-40 IU/DL. Treated or tested with DDAVP (between 1980 and 2013), and documented FVIII and VWF plasma levels prior to DDAVP administration and at least for 1 time point after DDAVP administration.

Exclusion criteria

Exclusion criteria: Severe hemophilia A patients (factor VIII

Design outcomes

Primary

Measure	Time frame
The main study parameters are: - Clinical factors that determine DDAVP response - Genetic factors that determine DDAVP response The main study endpoint is the response to DDAVP, which is defined as complete (1h after DDVP FVIII: C >0.50 IE/ml), partial (1h after DDVP FVIII: C 0.30-0.50 IE/ml), or none (1h after DDVP FVIII: C	—

Secondary

Measure	Time frame
N.a.	—

Countries

Netherlands

Outcome results